September 12th 2024
The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
TIMS effective for more than atopic dermatitis
February 8th 2004Tacrolimus and pimecrolimus may spring to mind first when atopic dermatitisis diagnosed, but it turns out that these topical immunomodulators are alsoeffective for a host of previously difficult-to-treat diseases. Granulomafaciale, Hailey Hailey disease, hand and foot eczema, and chronic actinicdermatitis are among the lengthy list of conditions these work well for,according to Mark Lebwohl, M.D., professor and chairman, departmentof dermatology, Mt. Sinai School of Medicine.
Clinical comparison pushes AD treatment toward potency chart
February 7th 2004Interim data from three studies released at the 62nd annual conferenceof the American Academy of Dermatology support preliminary data presentedlast month demonstrating that tacrolimus ointment (Protopic, Fujisawa) ismore effective than pimecrolimus cream (Elidel, Novartis) in the treatmentof adult and pediatric patients with atopic dermatitis.
Where will modern acne treatment take us?
February 1st 2004Laser and light therapies, while still controversial, are dramatically changing acne treatment. Rosacea patients also benefit from the more patient-friendly nondrug options. And drug therapies, including hormonal options, provide a strong hope that patients will have alternatives in treatment aimed at tackling severe acne in the future.
Panel moves to deconstruct itch
January 1st 2004Barcelona, Spain - Identifying the cause of itch is the key to treating it. New research is helping better characterize pruritus, leading to more effective therapies for this frustrating condition, according to physicians reporting at the 2003 meeting of the European Academy of Dermatology and Venereology (EADV).
Broaden your patients' treatment options
January 1st 2004Baltimore - PUVA and phototherapy are safe and effective for the treatment of more than two dozen conditions, but of the dermatologists who provide these treatments, as many as half use them solely for psoriasis, according to Warwick L. Morison M.D., professor of dermatology, Johns Hopkins Medical School, Baltimore.